In the News: Goldman Sachs-CSRC Settlement; First Sci-Tech Board Funds Approved; and Drug Administration Law Under Review

The CSRC has agreed its first administrative settlement with Goldman Sachs and Gao Hua Securities; seven themed funds were approved for Shanghai's new Sci-Tech Board; and the National People's Congress is reviewing measures to tighten up the production and sale of drugs.

3 minute read April 29, 2019 at 10:16 AM

Marilyn Romero

In the News: Goldman Sachs-CSRC Settlement; First Sci-Tech Board Funds Approved; and Drug Administration Law Under Review

CSRC agrees first administrative settlement with Goldman Sachs

The China Securities Regulatory Commission, or CSRC, has agreed to settle an internal control case against U.S. investment bank Goldman Sachs and its Chinese partner Gao Hua Securities for Rmb150 million, or $22.31 million.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)